mp.weixin.qq.com·· 6 hours agoPickScore89
Hengrui Reports Phase 3 HORIZON-Breast06: Ruzaltatug Median PFS 16.6 Months in Chemo-Naive HER2-Low Advanced Breast Cancer
In brief
Hengrui Pharma reported Phase 3 HORIZON-Breast06 results for ruzaltatug (SHR-A1811) in HER2-low advanced breast cancer. In chemotherapy-naive patients, median PFS was 16.6 months with ruzaltatug versus 6.8 months in the chemotherapy arm.
Why it matters
Source gives PFS versus chemotherapy and the hazard ratio, and notes cross-trial comparisons cannot substitute for head-to-head evidence.
Source: mp.weixin.qq.com · mp.weixin.qq.com